MiDerma

MAI Derma is a South Korean beauty-tech and biotechnology company specializing in advanced transdermal drug delivery systems and high-performance skincare solutions. Founded in 2021 and headquartered in Seoul, the company developed 'DermaPass,' an innovative, virtually painless microneedle device utilizing patented 34G R-Edge needles and semiconductor-level precision molding technology. Alongside its delivery platform, MAI Derma formulates its own active cosmetic ingredients and professional-grade skin boosters, including PDRN-based and redox-based formulations targeting skin regeneration, hyperpigmentation, and aging. The company operates on both B2B and B2C models, collaborating with major cosmetic brands while advancing its independent product lines toward a planned technology-driven IPO.